Financing ·
ALX Oncology Holdings Inc. entered into a secured multi-tranche term loan agreement with HSBC Ventures USA Inc. on…
ALXOAlx Oncology Holdings Inc
ALX Oncology Holdings Inc. entered into a secured multi-tranche term loan agreement with HSBC Ventures USA Inc. on June 25, 2026. The facility provides up to $50,000,000 in aggregate principal, including $10,000,000 that is uncommitted. The company immediately borrowed $10,000,000 to refinance existing debt with Oxford Finance and Silicon Valley Bank. An additional $20,000,000 is available through June 30, 2028, with another $10,000,000 contingent upon positive clinical data from the Phase 2 ASPEN-09 study of Evorpacept and Phase 1 study of ALX2004. The loans mature on June 1, 2030, and carry a floating interest rate equal to the greater of the Prime Rate or 6.0%. ALX Oncology is a biotechnology company focused on developing cancer therapies.